Arcutis (NASDAQ: ARQT) director Halley Gilbert receives RSUs and 16,667-share option grant

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Halley E. Gilbert reported equity awards rather than open-market trades. On June 5, 2026, Gilbert received 5,778 Restricted Stock Units (RSUs) in connection with service as a non-employee director. Each RSU will convert into one share of common stock when it vests.

The RSUs vest on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to continued service. On the same date, Gilbert was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule. Following the RSU grant, Gilbert directly owns 27,901 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gilbert Halley E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,667	$0.00	--
Grant/Award	Common Stock	5,778	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 16,667 shares (Direct, null); Common Stock — 27,901 shares (Direct, null)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Key Figures

RSU grant: 5,778 RSUs Stock option grant: 16,667 options Option exercise price: $21.23 per share +3 more

6 metrics

RSU grant 5,778 RSUs Granted June 5, 2026 for non-employee director service

Stock option grant 16,667 options Granted June 5, 2026 on common stock

Option exercise price $21.23 per share Conversion/exercise price of stock option grant

Common shares held 27,901 shares Total common stock directly owned after RSU grant

RSU vesting date June 5, 2026 Vest on earlier of this date or before next annual meeting

Option expiration June 5, 2036 Expiration date of stock option grant

Key Terms

Restricted Stock Units ("RSUs"), non-employee director, annual meeting of stockholders, vesting, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

non-employee director financial

"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders"

annual meeting of stockholders financial

"as of the Company's 2026 annual meeting of stockholders"

vesting financial

"upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 09:21 PM Accepted by SEC EDGAR 06/09/2026 - 09:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilbert Halley E

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		5,778(1)	A	$0	27,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.23	06/05/2026		A		16,667		(2)	06/05/2036	Common Stock	16,667	$0	16,667	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Remarks:

	/s/Latha Vairavan, as Attorney-in-Fact for Halley E. Gilbert	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Halley E. Gilbert report for Arcutis Biotherapeutics (ARQT)?

Halley E. Gilbert reported receiving equity awards, not open-market trades. He was granted 5,778 RSUs and a stock option for 16,667 shares, both tied to his service as a non-employee director and vesting over time.

How many Arcutis Biotherapeutics (ARQT) shares does Halley E. Gilbert hold after these awards?

After the June 5, 2026 RSU grant, Halley E. Gilbert directly holds 27,901 shares of Arcutis common stock. This figure reflects his ownership following the award of 5,778 RSUs, which will convert into shares upon future vesting.

What are the terms of the RSU grant to Halley E. Gilbert at Arcutis (ARQT)?

Gilbert received 5,778 RSUs as a non-employee director. Each RSU entitles him to one share of common stock upon vesting, which occurs on the earlier of June 5, 2026 or immediately before the next annual stockholder meeting, assuming continued service.

What are the key details of Halley E. Gilbert’s stock option grant from Arcutis (ARQT)?

Gilbert was granted a stock option for 16,667 shares of Arcutis common stock at an exercise price of $21.23 per share. The option vests 100% on the earlier of June 5, 2026 or immediately before the next annual meeting, subject to continued service.

Are Halley E. Gilbert’s reported Arcutis (ARQT) transactions considered purchases or compensation grants?

The reported transactions are compensation grants, not market purchases. Both the 5,778 RSUs and the 16,667-share stock option were awarded in connection with Gilbert’s role as a non-employee director, with vesting tied to his continued board service.